Home ReForm Biologics

ReForm Biologics

ReForm Biologics Announces Issuance of U.S. Patent for New Excipient to Improve Antibody-Based Therapeutics

“Many antibody-based therapeutics need to be delivered intravenously due to their high dose requirements and viscosity in...

ReForm Biologics Appoints John M. Sorvillo, Ph.D., as Chief Executive Officer

New CEO Appointed ReForm Biologics, a pharmaceutical technology company that develops proprietary excipients to improve biologic formulations, announced...